Announcement Summary

Entity name

GENETIC SIGNATURES LIMITED

Announcement Type

New announcement

Date of this announcement

21/12/2023

The Proposed issue is:

☑ A standard pro rata issue (including non-renounceable or renounceable)

☑ A placement or other type of issue

Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)

ASX +security code	+Security description	Maximum Number of +securities to be issued
GSS	ORDINARY FULLY PAID	21,564,811

Ex date

27/12/2023

+Record date

28/12/2023

Offer closing date

18/1/2024

Issue date

25/1/2024

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
GSS	ORDINARY FULLY PAID	21,510,899

Proposed +issue date

29/12/2023

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

GENETIC SIGNATURES LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ABN

30095913205

1.3 ASX issuer code

GSS

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

21/12/2023

1.6 The Proposed issue is:

☑ A standard +pro rata issue (non-renounceable or renounceable)

☑ A placement or other type of issue

1.6a The proposed standard +pro rata issue is:

Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

⊗ No

Part 3B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

GSS: ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ⊗ No If the entity has quoted company options, do the terms entitle option holders to participate on exercise?

⊗ No

Details of +securities proposed to be issued

ASX +security code and description

GSS: ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities are non CDIs)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)

The quantity of additional +securities to be issued For a given quantity of +securities held

20 133

What will be done with fractional entitlements?

Maximum number of +securities proposed to be issued (subject to rounding)

Fractions rounded up to the next whole number

21,564,811

Offer price details for retail security holders

In what currency will the offer be

What is the offer price per +security for the retail offer?

made?

AUD - Australian Dollar

AUD 0.37000

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? ⊗ No

Will a scale back be applied if the offer is over-subscribed? ⊗ No

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

✓ Yes

Part 3C - Timetable

3C.1 +Record date

28/12/2023

3C.2 Ex date

27/12/2023

3C.4 Record date

28/12/2023

3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue

2/1/2024

3C.6 Offer closing date

18/1/2024

3C.7 Last day to extend the offer closing date

15/1/2024

3C.9 Trading in new +securities commences on a deferred settlement basis

19/1/2024

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

25/1/2024

3C.12 Date trading starts on a normal T+2 basis

29/1/2024

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

31/1/2024

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer? ⊗ Yes

3E.1a Who is the lead manager/broker?

Bell Potter Securities Limited (AFSL 243480) and Taylor Collison Limited (AFSL 247083) are the Joint Lead Managers and Underwriters.

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Management fee of 3% of offer proceeds.

3E.2 Is the proposed offer to be underwritten?

Yes

3E.2a Who are the underwriter(s)?

Bell Potter Securities Limited (AFSL 243480) and Taylor Collison Limited (AFSL 247083) are the Joint Lead Managers and Underwriters.

3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?

Fully underwritten

3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?

Underwriting fee of 3% of offer proceeds.

3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated

Please refer to the summary of the Underwriting Agreement as provided in the Capital Raising Presentation as announced on 21 December 2023.

3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?

✓ Yes

3E.2e (i) What is the name of that party?

Chatonsky Superannuation Fund. Mr Stephane Chatonsky is a related party of the Chatonsky Superannuation Fund.

3E.2e (ii) What is the extent of their underwriting or sub-underwriting (ie the amount or proportion of the offer they have underwritten or sub-underwritten)?

\$75,000

3E.2e (iii) What fee, commission or other consideration is payable to them for acting as underwriter or sub-underwriter?

Nil.

3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

☑ No

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Standard share registry, external advisers and ASX administrative fees.

Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

The funds raised from the offer will be used to undertake additional regulatory approvals, new customer installations, continued instrument and product development and for general working capital and capital raising costs.

3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?

☑ No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?

⊗ No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue

Security holders outside Australia and New Zealand

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

Yes

3F.5a Please provide further details of the offer to eligible beneficiaries

This will be undertaken through the offer process managed by Boardroom Pty Limited.

3F.6 URL on the entity's website where investors can download information about the proposed issue

https://geneticsignatures.com/au/investors/announcements/

3F.7 Any other information the entity wishes to provide about the proposed issue

3F.8 Will the offer of rights under the rights issue be made under a disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?
⊗ No

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

☑ The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description

GSS: ORDINARY FULLY PAID

Number of +securities proposed to be issued

21,510,899

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

What is the issue price per

+security?

AUD - Australian Dollar AUD 0.37000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ☑ Yes Part 7C - Timetable

7C.1 Proposed +issue date

29/12/2023

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
☑ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

✓ Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

21,510,899 fully paid ordinary shares

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☑ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? $\stackrel{\frown}{N}$ $\stackrel{\frown}{N}$

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

☑ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

✓ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

⊗ Yes

7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited (AFSL 243480) and Taylor Collison Limited (AFSL 247083) are the Joint Lead Managers

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Management fee of 3% of offer proceeds plus selling fee of 3% of offer proceeds.

7E.2 Is the proposed issue to be underwritten?

☑ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the pro-	posed issue
---	-------------

N/A

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

The funds raised from the offer will be used to undertake additional regulatory approvals, new customer installations, continued instrument and product development and for general working capital and capital raising costs.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? $\ensuremath{\mathfrak{C}}$ No

7F.2 Any other information the entity wishes to provide about the proposed issue

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

☑ The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)